MA27731A1 - Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete - Google Patents

Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete

Info

Publication number
MA27731A1
MA27731A1 MA28562A MA28562A MA27731A1 MA 27731 A1 MA27731 A1 MA 27731A1 MA 28562 A MA28562 A MA 28562A MA 28562 A MA28562 A MA 28562A MA 27731 A1 MA27731 A1 MA 27731A1
Authority
MA
Morocco
Prior art keywords
methyl
phenyl
fluoro
bis
ethyl
Prior art date
Application number
MA28562A
Other languages
English (en)
Inventor
Melotto Sergio
Corsi Mauro
Carletti Renzo
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27731A1 publication Critical patent/MA27731A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Associations comprenant de la paroxétine et du [1-(R)-(3,5-bis-trifluoro-2-méthylphényl)-éthyl]-méthylamide d'acide 2-(S)-(4-fluoro-2-méthylphényl)-pipérazine-1-carboxylique pour le traitement de la dépression et/ou de l'anxiété La présente invention concerne des associations thérapeutiques comprenant de la paroxétine ou ses sels ou produits de solvatation physiologiquement acceptables et du [1-(R)-(3, 5-bis-trifluorométhyl-phényl)-éthyl]-méthylamide d'acide 2-(S)-(4-fluoro-2-méthyl-phényl)-pipérazine-1-carboxylique ou ses sels ou produits de solvatation physiologiquement acceptables, des compositions pharmaceutiques contenant lesdites associations, et leur utilisation dans le traitement de la dépression et/ou de l'anxiété.
MA28562A 2003-04-17 2005-10-19 Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete MA27731A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments

Publications (1)

Publication Number Publication Date
MA27731A1 true MA27731A1 (fr) 2006-01-02

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28561A MA27730A1 (fr) 2003-04-17 2005-10-19 Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
MA28562A MA27731A1 (fr) 2003-04-17 2005-10-19 Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA28561A MA27730A1 (fr) 2003-04-17 2005-10-19 Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete

Country Status (18)

Country Link
US (4) US20060241143A1 (fr)
EP (4) EP1653956A1 (fr)
JP (4) JP2006523651A (fr)
KR (2) KR20060003875A (fr)
CN (2) CN1809355A (fr)
AU (2) AU2004229181A1 (fr)
BR (2) BRPI0409377A (fr)
CA (2) CA2522311A1 (fr)
CO (1) CO5700753A2 (fr)
GB (1) GB0308968D0 (fr)
IS (2) IS8129A (fr)
MA (2) MA27730A1 (fr)
MX (2) MXPA05011063A (fr)
NO (2) NO20055367L (fr)
PL (2) PL377857A1 (fr)
RU (2) RU2005135647A (fr)
WO (4) WO2004091616A1 (fr)
ZA (2) ZA200508067B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (fr) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Forme dosifee stable d'un antidepresseur
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
WO2012175434A1 (fr) * 2011-06-20 2012-12-27 Glaxo Group Limited Formulations pharmaceutiques comprenant du vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
JP2001523245A (ja) * 1997-04-24 2001-11-20 メルク シヤープ エンド ドーム リミテツド 肥満を治療するためのｎｋ−１受容体拮抗薬およびｓｓｒｉの使用
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
ATE318259T1 (de) * 1999-12-17 2006-03-15 Schering Corp Selektive neurokinin-antagonisten
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
CA2466465A1 (fr) * 2001-11-13 2003-05-22 Schering Corporation Antagonistes de nk1
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CN1809359A (zh) 2006-07-26
MXPA05011063A (es) 2005-12-12
CA2522313A1 (fr) 2004-10-28
EP1615642A1 (fr) 2006-01-18
US20060287325A1 (en) 2006-12-21
JP2006523652A (ja) 2006-10-19
IS8128A (is) 2005-11-15
MA27730A1 (fr) 2006-01-02
NO20055368L (no) 2005-11-14
RU2005135647A (ru) 2006-06-10
AU2004229179A1 (en) 2004-10-28
ZA200508068B (en) 2007-02-28
CN1809355A (zh) 2006-07-26
US20060241124A1 (en) 2006-10-26
MXPA05011064A (es) 2006-04-18
US20060241143A1 (en) 2006-10-26
WO2004091624A1 (fr) 2004-10-28
CO5700753A2 (es) 2006-11-30
AU2004229181A1 (en) 2004-10-28
JP2006523650A (ja) 2006-10-19
JP2006523651A (ja) 2006-10-19
CA2522311A1 (fr) 2004-10-28
IS8129A (is) 2005-11-15
EP1615641A1 (fr) 2006-01-18
WO2004091616A1 (fr) 2004-10-28
EP1613325A1 (fr) 2006-01-11
GB0308968D0 (en) 2003-05-28
NO20055367L (no) 2005-11-14
WO2004091615A1 (fr) 2004-10-28
PL377857A1 (pl) 2006-02-20
BRPI0409377A (pt) 2006-04-25
US20060217395A1 (en) 2006-09-28
EP1653956A1 (fr) 2006-05-10
PL377858A1 (pl) 2006-02-20
KR20060003876A (ko) 2006-01-11
WO2004091617A1 (fr) 2004-10-28
ZA200508067B (en) 2007-02-28
RU2005135649A (ru) 2006-03-20
BRPI0409379A (pt) 2006-04-25
JP2006523649A (ja) 2006-10-19
KR20060003875A (ko) 2006-01-11

Similar Documents

Publication Publication Date Title
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
JP2005532372A5 (fr)
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DZ2549A1 (fr) Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan.
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
HUP0303082A2 (hu) Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
MA27021A1 (fr) Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
BRPI0414448A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
MA27474A1 (fr) Vaccin
HUP0402092A2 (hu) 2-[5-(4-Fluorfenil)-3-piridilmetilaminometil]-kromán vegyületek és fiziológiásan elfogadható sói alkalmazása gyógyszerkészítmények előállítására
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
MA28224A1 (fr) Nitro-oxyderives de medicaments contre l'hypertension.
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion